FDA approves RYBREVANT® with chemotherapy for first-line NSCLC with EGFR exon 20 insertion mutations.

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy is the first FDA-approved therapy for first-line treatment of patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The approval is based on the Phase 3 PAPILLON study results, which demonstrated that RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61% versus chemotherapy alone in previously untreated NSCLC patients with EGFR exon 20 insertion mutations. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) have updated their recommendations to include RYBREVANT® plus chemotherapy as a preferred first-line regimen for patients with NSCLC with EGFR exon 20 insertion mutations.

March 01, 2024
16 Articles